Strides Acrolab to raise 1500 crore
Advertisement
Drug firm Strides Arcolab is expected to raise Rs 1,500 crore through various market instruments. It will be raising the funds by way of issuing GDRs/ADRs/FCCBs, QIP or such other equity linked instruments, the company said.
"The Board of Directors of the company have approved the proposal to raise long term funds by way of issue of GDRs/ADRs /FCCBs/QIP or such other equity linked instruments as may be permissible for an amount up to Rs 1,500 crore including a green shoe option," Strides Arcolab said in a BSE filing.
It added: "The fund raising is subject to shareholders' approval and such other statutory approvals as may be required including that of Foreign Investment Promotion Board.
Strides Arcolab has been on a acquisition spree when earlier in May this year, the company signed a deal to accquire South African drugmaker Aspen Pharmacare's generic pharmaceutical business in Australia and also, certain branded pharma assets, as reported by vccircle.com.
Last year, it struck three deals including two in India. The company made a strategic investment in Oncobiologics Inc and also bought a majority stake in branded generics business of Chennai-based Bafna Pharmaceutical and announced an all-stock deal to buy Shasun Pharma.
Founded in 1990, the company offers general tablets, hard- and soft-gelatin capsules, sachets, potent drugs and semi-solids.
"The Board of Directors of the company have approved the proposal to raise long term funds by way of issue of GDRs/ADRs /FCCBs/QIP or such other equity linked instruments as may be permissible for an amount up to Rs 1,500 crore including a green shoe option," Strides Arcolab said in a BSE filing.
It added: "The fund raising is subject to shareholders' approval and such other statutory approvals as may be required including that of Foreign Investment Promotion Board.
Strides Arcolab has been on a acquisition spree when earlier in May this year, the company signed a deal to accquire South African drugmaker Aspen Pharmacare's generic pharmaceutical business in Australia and also, certain branded pharma assets, as reported by vccircle.com.
Last year, it struck three deals including two in India. The company made a strategic investment in Oncobiologics Inc and also bought a majority stake in branded generics business of Chennai-based Bafna Pharmaceutical and announced an all-stock deal to buy Shasun Pharma.
Founded in 1990, the company offers general tablets, hard- and soft-gelatin capsules, sachets, potent drugs and semi-solids.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.